AltheRx™ Pharmaceuticals is a privately held, clinical development company focused on advancing best-in-class compounds with high promise in large unmet markets. Its lead product, Solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS). AltheRx is focused on creating strategic partnerships that complement its development and commercialization capabilities globally for this promising medicine.  Learn more >

MAY 30, 2013
AltheRx Pharmaceuticals Appoints Michael R Dougherty to Board of Directors

MAY 6, 2013
AltheRx Presents Data on Improved Efficacy in an Experimental Combination of Beta3-Adrenoceptor Agonists and Antimuscarinics at AUA Annual Meeting

- Efficacy and potency of solabegron significantly increased in the presence of antimuscarinic agents in bladder muscle contraction model -
 

- Results support advancing combination therapy into the clinic for further study in urinary bladder dysfunction -